Human immunovirus (HIV) is a wide-spread and incurably lethal
disease. The Blood-Brain-Barrier (BBB) separates the brain tissue from the
bloodstream and is intended to keep the brain safe from potentially toxic
molecules within the bloodstream. One of the more insidious aspects of HIV is
the capacity of the virus to ‘hide’ within the brain tissue where most anti-viral
medications cannot reach it due to the BBB. This makes treating HIV
particularly difficult as the virus can re-infest a patient from surviving
copies in the brain tissue, even if the majority of the viral replicates have
been destroyed. Recently, researchers at Universidade do Porto (Portugal) and University
of Helsinki (Finland) used fluorescent PLGA-FKR648 (PolyVivo AV015) from
PolySciTech (www.polyscitech.com) as
part of development of BBB crossing nanoparticles to attack HIV virus which hides
in the brain. This fluorescently-tagged PLGA was used to develop nanoparticles which
could be tracked by microscopy to observe their uptake across the barrier. By visualizing
these particles, the researchers were able to validate the success of their
particles in crossing the BBB. This research holds promise for improved
therapeutic options for HIV. Read more: Martins,
Cláudia, Francisca Araújo, Maria João Gomes, Carlos Fernandes, Rute Nunes, Wei
Li, Hélder A. Santos, Fernanda Borges, and Bruno Sarmento. "Using
microfluidic platforms to develop CNS-targeted polymeric nanoparticles for HIV
therapy." European Journal of Pharmaceutics and Biopharmaceutics (2018). https://www.sciencedirect.com/science/article/pii/S0939641117314820
“Abstract: The human immunodeficiency virus (HIV) uses the
brain as reservoir, which turns it as a promising target to fight this
pathology. Nanoparticles (NPs) of poly(lactic-co-glycolic) acid (PLGA) are
potential carriers of anti-HIV drugs to the brain, since most of these antiretrovirals,
as efavirenz (EFV), cannot surpass the blood–brain barrier (BBB). Forasmuch as
the conventional production methods lack precise control over the final
properties of particles, microfluidics emerged as a prospective alternative.
This study aimed at developing EFV-loaded PLGA NPs through a conventional and
microfluidic method, targeted to the BBB, in order to treat HIV neuropathology.
Compared to the conventional method, NPs produced through microfluidics
presented reduced size (73 nm versus 133 nm), comparable polydispersity (around
0.090), less negative zeta-potential (−14.1 mV versus −28.0 mV), higher EFV
association efficiency (80.7% versus 32.7%) and higher drug loading (10.8%
versus 3.2%). The microfluidics-produced NPs also demonstrated a sustained in
vitro EFV release (50% released within the first 24 h). NPs functionalization
with a transferrin receptor-binding peptide, envisaging BBB targeting, proved
to be effective concerning nuclear magnetic resonance analysis (δ = −0.008 ppm;
δ = −0.017 ppm). NPs demonstrated to be safe to BBB endothelial and neuron
cells (metabolic activity above 70%), as well as non-hemolytic (1–2% of
hemolysis, no morphological alterations on erythrocytes). Finally,
functionalized nanosystems were able to interact more efficiently with BBB
cells, and permeability of EFV associated with NPs through a BBB in vitro model
was around 1.3-fold higher than the free drug. Keywords: Nanoparticles; Human
immunodeficiency virus; Microfluidic production; Targeting; Blood-brain barrier”
No comments:
Post a Comment